Oppenheimer & Co. Inc. Sells 2,363 Shares of Cellectis SA (CLLS)

Oppenheimer & Co. Inc. decreased its position in shares of Cellectis SA (NASDAQ:CLLS) by 7.9% during the third quarter, HoldingsChannel reports. The institutional investor owned 27,499 shares of the biotechnology company’s stock after selling 2,363 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Cellectis were worth $776,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of CLLS. FMR LLC grew its position in shares of Cellectis by 18.0% during the 2nd quarter. FMR LLC now owns 4,240,010 shares of the biotechnology company’s stock worth $119,949,000 after buying an additional 647,164 shares in the last quarter. BlackRock Inc. grew its position in shares of Cellectis by 259.7% during the 2nd quarter. BlackRock Inc. now owns 443,713 shares of the biotechnology company’s stock worth $12,552,000 after buying an additional 320,340 shares in the last quarter. Nexthera Capital LP boosted its position in Cellectis by 64.7% during the second quarter. Nexthera Capital LP now owns 548,212 shares of the biotechnology company’s stock valued at $15,509,000 after purchasing an additional 215,458 shares in the last quarter. Laurion Capital Management LP bought a new stake in Cellectis during the second quarter valued at about $5,658,000. Finally, ARK Investment Management LLC boosted its position in Cellectis by 178.8% during the second quarter. ARK Investment Management LLC now owns 244,263 shares of the biotechnology company’s stock valued at $6,910,000 after purchasing an additional 156,666 shares in the last quarter. 27.11% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts recently weighed in on CLLS shares. BidaskClub downgraded Cellectis from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 14th. ValuEngine downgraded Cellectis from a “buy” rating to a “hold” rating in a research report on Wednesday, October 24th. Zacks Investment Research downgraded Cellectis from a “buy” rating to a “hold” rating in a research report on Tuesday, July 10th. Finally, Barclays started coverage on Cellectis in a research report on Monday, July 16th. They set an “overweight” rating and a $50.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $49.75.

Shares of CLLS stock opened at $26.84 on Tuesday. Cellectis SA has a 1-year low of $22.62 and a 1-year high of $38.85.

TRADEMARK VIOLATION WARNING: This news story was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/11/06/oppenheimer-co-inc-sells-2363-shares-of-cellectis-sa-clls.html.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).

Recommended Story: What is Cost of Capital?

Want to see what other hedge funds are holding CLLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellectis SA (NASDAQ:CLLS).

Institutional Ownership by Quarter for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply